Compare GLBS & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLBS | BOLD |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.4M | 60.8M |
| IPO Year | 2010 | 2024 |
| Metric | GLBS | BOLD |
|---|---|---|
| Price | $3.07 | $2.43 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 129.7K | ★ 199.4K |
| Earning Date | 11-27-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $39.12 | N/A |
| Revenue Next Year | $2.76 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.04 | $0.96 |
| 52 Week High | $4.06 | $3.16 |
| Indicator | GLBS | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 38.57 | 37.70 |
| Support Level | $2.71 | $1.40 |
| Resistance Level | $3.19 | $2.71 |
| Average True Range (ATR) | 0.21 | 0.16 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 24.24 | 25.58 |
Globus Maritime Ltd is a dry bulk shipping company that provides marine transportation services internationally. The company owns, operates, and manages a fleet of dry bulk vessels that transport iron ore, coal, grain, steel products, cement, alumina, and other dry bulk cargo. Its operations are managed by its subsidiary which also provides in-house commercial and technical management for its vessels and also offers consulting services for an affiliated ship management company. It generates maximum revenues by charging customers for the use of vessels to transport dry bulk commodities.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.